Genta - der letzte Thread
16:16:48 0,577 500
16:16:42 0,577 1800
16:16:30 0,560 2000
16:16:24 0,575 1000
16:15:11 0,570 700
16:14:13 0,570 1000
16:13:48 0,535 1000
16:13:13 0,570 1000
16:13:09 0,557 5601
Optionen
| Boardmail an "doc-t" |
Wertpapier: Genta |
waren sie dann teurer.
Optionen
| Boardmail an "einstein16" |
Wertpapier: Genta |
CALGARY, Alberta, Sept. 18, 2009 (GLOBE NEWSWIRE) -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Genta Incorporated (OTCBB:GETA). Skymark Research is currently offering a complimentary trial subscription. To view our research go to: www.skymarkresearch.com
About SMR:
Skymark Research is a leading provider of independent investment research in North America. Our services include research analysis on the small- and micro-cap markets, real-time news and financial data, market commentary and the SMR newsletter. Skymark Research's staff of small-cap investment professionals is dedicated to providing the small market's investment community with the tools and avenues necessary to make the important investment decisions. To view our research reports on a complimentary trial basis and take advantage of our other services, go to www.skymarkresearch.com and click on the complimentary trial subscription button on our home page, or go directly to our registration page at www.skymarkresearch.com/signup.php
About Genta Incorporated (OTCBB:GETA):
Genta Incorporated (OTCBB:GETA) is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, which has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States.
SMR Disclosure:
Skymarkresearch.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Skymark Research has not been compensated by any of the above mentioned companies. Please read our report and visit our Web site, www.skymarkresearch.com, for complete risks and disclosures.
10:38:46 Q 0.87 -0.065 200
10:38:45 Q 0.86 -0.075 300
10:38:45 Q 0.87 -0.065 5,000
10:38:33 Q 0.851 -0.084 3,000
10:38:33 Q 0.851 -0.084 5,000
10:38:33 Q 0.851 -0.084 1,933
10:38:33 Q 0.851 -0.084 100
10:38:33 Q 0.851 -0.084 600
10:38:24 Q 0.85 -0.085 5,000
10:38:22 Q 0.85 -0.085 5,000
Stay long and strong.
Meine Wamus ziehen auch wieder an.
Optionen
| Boardmail an "einstein16" |
Wertpapier: Genta |
Optionen
| Boardmail an "einstein16" |
Wertpapier: Genta |